{ "x402Version": 2, "id": 39500, "slug": "39500", "resource": "https://api.magentlab.com/api/calc/impede_vte", "description": "Sanfilippo 2019 IMPEDE VTE for multiple myeloma: IMiD 4, BMI>=25 1, pelvic/hip/femur fracture 4, ESA 1, doxorubicin 3, dexamethasone none/low/high 0/2/4 (high if monthly >160 mg), Asian/Pacific Islander -3 (caller-assigned), VTE history 5, tunneled line 2, thromboprophylaxis none/prophylactic/therapeutic 0/-3/-4. Unclamped. <=3 low 3.3%, 4-7 intermediate 8.3%, >=8 high 15.2%. Not a prophylaxis order. Not SAVED or Khorana.", "type": "http", "serviceName": "magent", "resourceType": "Agent Service", "accepts": [ { "scheme": "exact", "network": "eip155:8453", "payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2", "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913", "amount": "5000", "amountUsd": 0.005, "maxTimeoutSeconds": 600 } ], "outputSchema": { "properties": { "example": { "type": "object" }, "type": { "type": "string" } }, "required": [ "type" ], "type": "object" }, "extensions": { "bazaar": { "info": { "iconUrl": "https://api.magentlab.com/favicon.ico", "input": { "body": { "items": [ { "asian_pacific_islander": false, "bmi_ge_25": false, "dexamethasone": "none", "doxorubicin": false, "esa": false, "imid": false, "pelvic_hip_femur_fracture": false, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false }, { "asian_pacific_islander": false, "bmi_ge_25": false, "dexamethasone": "none", "doxorubicin": false, "esa": false, "imid": false, "pelvic_hip_femur_fracture": false, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false } ] }, "method": "POST", "type": "http" }, "output": { "example": { "count": 2, "items": [ { "asian_pacific_islander": false, "bmi_ge_25": false, "citation": { "authors": "Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF", "doi": "10.1002/ajh.25603", "id": "sanfilippo-2019-impede", "pmid": "31374145", "source": "Am J Hematol. 2019;94(11):1176-1184", "title": "Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score" }, "components": [ { "factor": "imid", "points": 0, "present": false }, { "factor": "bmi_ge_25", "points": 0, "present": false }, { "factor": "pelvic_hip_femur_fracture", "points": 0, "present": false }, { "factor": "esa", "points": 0, "present": false }, { "factor": "doxorubicin", "points": 0, "present": false }, { "factor": "dexamethasone", "points": 0, "present": false, "value": "none" }, { "factor": "asian_pacific_islander", "points": 0, "present": false }, { "factor": "vte_history", "points": 0, "present": false }, { "factor": "tunneled_line", "points": 0, "present": false }, { "factor": "thromboprophylaxis", "points": 0, "present": false, "value": "none" } ], "dexamethasone": "none", "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.", "doxorubicin": false, "esa": false, "formula": "impede_vte", "formula_expression": "IMPEDE VTE (Sanfilippo 2019 Table 3) = imid (4) + bmi_ge_25 (1) + pelvic_hip_femur_fracture (4) + esa (1) + doxorubicin (3) + dexamethasone (none 0, low 2, high 4; high if total monthly dosing >160 mg) + asian_pacific_islander (-3) + vte_history (5) + tunneled_line (2) + thromboprophylaxis (none 0, prophylactic -3, therapeutic -4); unclamped; <=3 low 3.3%, 4-7 intermediate 8.3%, >=8 high 15.2%", "imid": false, "max_score": 24, "pelvic_hip_femur_fracture": false, "risk": "low", "score": 0, "six_month_vte_percent": 3.3, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false }, { "asian_pacific_islander": false, "bmi_ge_25": false, "citation": { "authors": "Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF", "doi": "10.1002/ajh.25603", "id": "sanfilippo-2019-impede", "pmid": "31374145", "source": "Am J Hematol. 2019;94(11):1176-1184", "title": "Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score" }, "components": [ { "factor": "imid", "points": 0, "present": false }, { "factor": "bmi_ge_25", "points": 0, "present": false }, { "factor": "pelvic_hip_femur_fracture", "points": 0, "present": false }, { "factor": "esa", "points": 0, "present": false }, { "factor": "doxorubicin", "points": 0, "present": false }, { "factor": "dexamethasone", "points": 0, "present": false, "value": "none" }, { "factor": "asian_pacific_islander", "points": 0, "present": false }, { "factor": "vte_history", "points": 0, "present": false }, { "factor": "tunneled_line", "points": 0, "present": false }, { "factor": "thromboprophylaxis", "points": 0, "present": false, "value": "none" } ], "dexamethasone": "none", "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.", "doxorubicin": false, "esa": false, "formula": "impede_vte", "formula_expression": "IMPEDE VTE (Sanfilippo 2019 Table 3) = imid (4) + bmi_ge_25 (1) + pelvic_hip_femur_fracture (4) + esa (1) + doxorubicin (3) + dexamethasone (none 0, low 2, high 4; high if total monthly dosing >160 mg) + asian_pacific_islander (-3) + vte_history (5) + tunneled_line (2) + thromboprophylaxis (none 0, prophylactic -3, therapeutic -4); unclamped; <=3 low 3.3%, 4-7 intermediate 8.3%, >=8 high 15.2%", "imid": false, "max_score": 24, "pelvic_hip_femur_fracture": false, "risk": "low", "score": 0, "six_month_vte_percent": 3.3, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false } ], "path": "/api/calc/impede_vte" }, "type": "json" } }, "schema": { "$schema": "https://json-schema.org/draft/2020-12/schema", "properties": { "input": { "additionalProperties": false, "properties": { "body": { "additionalProperties": false, "properties": { "items": { "items": { "properties": { "asian_pacific_islander": { "description": "Caller-assigned ethnicity/race Asian/Pacific Islander as used in Sanfilippo 2019. true or false. magent does not assign race or ethnicity. −3 if true.", "type": "boolean" }, "bmi_ge_25": { "description": "BMI ≥25 kg/m2 as assigned by the caller (Sanfilippo 2019 Table 3). true or false. magent does not compute BMI from height or weight. 1 point if true.", "type": "boolean" }, "dexamethasone": { "description": "Dexamethasone as assigned by the caller (Sanfilippo 2019 Table 3). none (not on dexamethasone) scores 0; low (dexamethasone used at total monthly dosing ≤160 mg) scores 2; high (total monthly dosing >160 mg) scores 4. Not the NCCN ≥480 mg definition.", "enum": [ "none", "low", "high" ], "type": "string" }, "doxorubicin": { "description": "Doxorubicin as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 3 points if true.", "type": "boolean" }, "esa": { "description": "Erythropoiesis-stimulating agent as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 1 point if true.", "type": "boolean" }, "imid": { "description": "Immunomodulatory drug (IMiD) as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 4 points if true.", "type": "boolean" }, "pelvic_hip_femur_fracture": { "description": "Pelvic, hip, or femur fracture as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 4 points if true.", "type": "boolean" }, "thromboprophylaxis": { "description": "Existing thromboprophylaxis as assigned by the caller (Sanfilippo 2019 Table 3). Mutually exclusive. none scores 0; prophylactic (prophylactic LMWH or aspirin) scores −3; therapeutic (therapeutic LMWH or warfarin) scores −4.", "enum": [ "none", "prophylactic", "therapeutic" ], "type": "string" }, "tunneled_line": { "description": "Tunneled line / central venous catheter as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 2 points if true.", "type": "boolean" }, "vte_history": { "description": "History of VTE before multiple myeloma as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 5 points if true.", "type": "boolean" } }, "required": [ "imid", "bmi_ge_25", "pelvic_hip_femur_fracture", "esa", "doxorubicin", "dexamethasone", "asian_pacific_islander", "vte_history", "tunneled_line", "thromboprophylaxis" ], "type": "object" }, "maxItems": 25, "minItems": 1, "type": "array" } }, "required": [ "items" ], "type": "object" }, "headers": { "additionalProperties": { "type": "string" }, "type": "object" }, "method": { "const": "POST", "type": "string" }, "type": { "const": "http", "type": "string" } }, "required": [ "type", "method" ], "type": "object" }, "output": { "properties": { "example": { "type": "object" }, "type": { "type": "string" } }, "required": [ "type" ], "type": "object" } }, "required": [ "input" ], "type": "object" } } }, "tags": [ "impede-vte", "vte", "myeloma", "thrombosis", "score", "bazaar" ], "sourceHost": "api.magentlab.com", "lastUpdated": "2026-10-12T14:15:36.327Z", "quality": { "calls30d": 4, "uniquePayers30d": 2, "lastCalledAt": "2026-10-12T14:15:36.191Z" }, "metadata": { "serviceName": "magent", "extensions": { "bazaar": { "info": { "iconUrl": "https://api.magentlab.com/favicon.ico", "input": { "body": { "items": [ { "asian_pacific_islander": false, "bmi_ge_25": false, "dexamethasone": "none", "doxorubicin": false, "esa": false, "imid": false, "pelvic_hip_femur_fracture": false, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false }, { "asian_pacific_islander": false, "bmi_ge_25": false, "dexamethasone": "none", "doxorubicin": false, "esa": false, "imid": false, "pelvic_hip_femur_fracture": false, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false } ] }, "method": "POST", "type": "http" }, "output": { "example": { "count": 2, "items": [ { "asian_pacific_islander": false, "bmi_ge_25": false, "citation": { "authors": "Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF", "doi": "10.1002/ajh.25603", "id": "sanfilippo-2019-impede", "pmid": "31374145", "source": "Am J Hematol. 2019;94(11):1176-1184", "title": "Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score" }, "components": [ { "factor": "imid", "points": 0, "present": false }, { "factor": "bmi_ge_25", "points": 0, "present": false }, { "factor": "pelvic_hip_femur_fracture", "points": 0, "present": false }, { "factor": "esa", "points": 0, "present": false }, { "factor": "doxorubicin", "points": 0, "present": false }, { "factor": "dexamethasone", "points": 0, "present": false, "value": "none" }, { "factor": "asian_pacific_islander", "points": 0, "present": false }, { "factor": "vte_history", "points": 0, "present": false }, { "factor": "tunneled_line", "points": 0, "present": false }, { "factor": "thromboprophylaxis", "points": 0, "present": false, "value": "none" } ], "dexamethasone": "none", "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.", "doxorubicin": false, "esa": false, "formula": "impede_vte", "formula_expression": "IMPEDE VTE (Sanfilippo 2019 Table 3) = imid (4) + bmi_ge_25 (1) + pelvic_hip_femur_fracture (4) + esa (1) + doxorubicin (3) + dexamethasone (none 0, low 2, high 4; high if total monthly dosing >160 mg) + asian_pacific_islander (-3) + vte_history (5) + tunneled_line (2) + thromboprophylaxis (none 0, prophylactic -3, therapeutic -4); unclamped; <=3 low 3.3%, 4-7 intermediate 8.3%, >=8 high 15.2%", "imid": false, "max_score": 24, "pelvic_hip_femur_fracture": false, "risk": "low", "score": 0, "six_month_vte_percent": 3.3, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false }, { "asian_pacific_islander": false, "bmi_ge_25": false, "citation": { "authors": "Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF", "doi": "10.1002/ajh.25603", "id": "sanfilippo-2019-impede", "pmid": "31374145", "source": "Am J Hematol. 2019;94(11):1176-1184", "title": "Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score" }, "components": [ { "factor": "imid", "points": 0, "present": false }, { "factor": "bmi_ge_25", "points": 0, "present": false }, { "factor": "pelvic_hip_femur_fracture", "points": 0, "present": false }, { "factor": "esa", "points": 0, "present": false }, { "factor": "doxorubicin", "points": 0, "present": false }, { "factor": "dexamethasone", "points": 0, "present": false, "value": "none" }, { "factor": "asian_pacific_islander", "points": 0, "present": false }, { "factor": "vte_history", "points": 0, "present": false }, { "factor": "tunneled_line", "points": 0, "present": false }, { "factor": "thromboprophylaxis", "points": 0, "present": false, "value": "none" } ], "dexamethasone": "none", "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.", "doxorubicin": false, "esa": false, "formula": "impede_vte", "formula_expression": "IMPEDE VTE (Sanfilippo 2019 Table 3) = imid (4) + bmi_ge_25 (1) + pelvic_hip_femur_fracture (4) + esa (1) + doxorubicin (3) + dexamethasone (none 0, low 2, high 4; high if total monthly dosing >160 mg) + asian_pacific_islander (-3) + vte_history (5) + tunneled_line (2) + thromboprophylaxis (none 0, prophylactic -3, therapeutic -4); unclamped; <=3 low 3.3%, 4-7 intermediate 8.3%, >=8 high 15.2%", "imid": false, "max_score": 24, "pelvic_hip_femur_fracture": false, "risk": "low", "score": 0, "six_month_vte_percent": 3.3, "thromboprophylaxis": "none", "tunneled_line": false, "vte_history": false } ], "path": "/api/calc/impede_vte" }, "type": "json" } }, "schema": { "$schema": "https://json-schema.org/draft/2020-12/schema", "properties": { "input": { "additionalProperties": false, "properties": { "body": { "additionalProperties": false, "properties": { "items": { "items": { "properties": { "asian_pacific_islander": { "description": "Caller-assigned ethnicity/race Asian/Pacific Islander as used in Sanfilippo 2019. true or false. magent does not assign race or ethnicity. −3 if true.", "type": "boolean" }, "bmi_ge_25": { "description": "BMI ≥25 kg/m2 as assigned by the caller (Sanfilippo 2019 Table 3). true or false. magent does not compute BMI from height or weight. 1 point if true.", "type": "boolean" }, "dexamethasone": { "description": "Dexamethasone as assigned by the caller (Sanfilippo 2019 Table 3). none (not on dexamethasone) scores 0; low (dexamethasone used at total monthly dosing ≤160 mg) scores 2; high (total monthly dosing >160 mg) scores 4. Not the NCCN ≥480 mg definition.", "enum": [ "none", "low", "high" ], "type": "string" }, "doxorubicin": { "description": "Doxorubicin as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 3 points if true.", "type": "boolean" }, "esa": { "description": "Erythropoiesis-stimulating agent as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 1 point if true.", "type": "boolean" }, "imid": { "description": "Immunomodulatory drug (IMiD) as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 4 points if true.", "type": "boolean" }, "pelvic_hip_femur_fracture": { "description": "Pelvic, hip, or femur fracture as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 4 points if true.", "type": "boolean" }, "thromboprophylaxis": { "description": "Existing thromboprophylaxis as assigned by the caller (Sanfilippo 2019 Table 3). Mutually exclusive. none scores 0; prophylactic (prophylactic LMWH or aspirin) scores −3; therapeutic (therapeutic LMWH or warfarin) scores −4.", "enum": [ "none", "prophylactic", "therapeutic" ], "type": "string" }, "tunneled_line": { "description": "Tunneled line / central venous catheter as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 2 points if true.", "type": "boolean" }, "vte_history": { "description": "History of VTE before multiple myeloma as assigned by the caller (Sanfilippo 2019 Table 3). true or false. 5 points if true.", "type": "boolean" } }, "required": [ "imid", "bmi_ge_25", "pelvic_hip_femur_fracture", "esa", "doxorubicin", "dexamethasone", "asian_pacific_islander", "vte_history", "tunneled_line", "thromboprophylaxis" ], "type": "object" }, "maxItems": 25, "minItems": 1, "type": "array" } }, "required": [ "items" ], "type": "object" }, "headers": { "additionalProperties": { "type": "string" }, "type": "object" }, "method": { "const": "POST", "type": "string" }, "type": { "const": "http", "type": "string" } }, "required": [ "type", "method" ], "type": "object" }, "output": { "properties": { "example": { "type": "object" }, "type": { "type": "string" } }, "required": [ "type" ], "type": "object" } }, "required": [ "input" ], "type": "object" } } } }, "liveness": { "reliability": null }, "verified": false, "featured": false, "provider": { "host": "api.magentlab.com", "manifest_name": "api.magentlab.com", "source": "cdp-mirror", "source_manifest_url": "https://api.cdp.coinbase.com/platform/v2/x402/discovery/resources", "submitted_at": "2026-10-14T01:15:01.050Z" }, "exampleResponse": { "example": {}, "type": "string" } }